Apolipoprotein A5 (APOA5) Antibody (FITC)
455€ (200 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Name
Apolipoprotein A5 (APOA5) Antibody (FITC)
Category
Primary Antibodies
Provider
Abbexa
Reference
abx271279
Tested Applications
WB, IHC, IF/ICC
Description
Apolipoprotein A5 (APOA5) Antibody (FITC) is a Rabbit Polyclonal antibody conjugated to FITC against Apolipoprotein A5 (APOA5).
Documentos del producto
Instrucciones
Data sheet
Especificaciones del producto
| Category | Primary Antibodies |
| Immunogen Target | Target: Apolipoprotein A5 (APOA5) |
| Host | Rabbit |
| Reactivity | Rat |
| Detection Method | Laser Line: 488 Excitation/Emission: 499/515 |
| Recommended Dilution | WB: 0.5-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | FITC |
| Isotype | IgG |
| Purification | Purified by antigen-specific affinity chromatography. |
| Size 1 | 200 µl |
| Size 2 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-15 working days. |
| Storage | Aliquot and store at 4°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | APOA5, APOAV, RAP3, apolipoprotein A5, APO A5,APO A-5,Apolipoprotein A-V |
| Background | Antibody anti-APOA5 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Background
APOA5 is a critical regulator of plasma triglyceride (TG) levels, playing an essential role in lipid metabolism and cardiovascular health It is primarily synthesized in the liver and is a minor apolipoprotein component of chylomicrons and very-low-density lipoproteins (VLDL) APOA5 functions by enhancing the activity of lipoprotein lipase (LPL), which hydrolyzes triglycerides in VLDL and chylomicrons, thereby reducing plasma triglyceride levels Genetic variants in the APOA5 gene are strongly associated with hypertriglyceridemia, which is a major risk factor for cardiovascular diseases (CVD), atherosclerosis, and pancreatitis APOA5 interacts with cell surface receptors such as GPIHBP1 to facilitate LPL activity and triglyceride clearance from the bloodstream Studies have shown that reduced APOA5 expression leads to elevated triglycerides and increased risk of metabolic syndrome APOA5 also modulates lipid storage in adipose tissue, highlighting its broader role in lipid homeostasis APOA5 is being investigated as a therapeutic target for hyperlipidemia and related cardiovascular conditions, as strategies enhancing APOA5 expression or function may improve triglyceride metabolism and reduce cardiovascular risks
Productos relacionados
Apolipoprotein A-V (APOA5) Antibody
APOA5 Antibody is a Rabbit Polyclonal antibody against APOA5. Apolipoprotein A5 (ApoA5) is fast gaining attention as a k…
Ver producto
Apolipoprotein A-V (APOA5) Antibody
Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mo…
Ver producto